# A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011

> **NCT07295496** · PHASE1 · RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 64 (estimated)

## Conditions studied

- Acute Gout Flare

## Interventions

- **DRUG:** IBI3011
- **DRUG:** IBI3011 Placebo

## Key facts

- **NCT ID:** NCT07295496
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-08
- **Primary completion:** 2026-06-07
- **Final completion:** 2026-06-07
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07295496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07295496, "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07295496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*